245 related articles for article (PubMed ID: 27180013)
1. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA
Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013
[TBL] [Abstract][Full Text] [Related]
2. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.
Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer MP; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Allard ML; Buckle RN; Gauuan PJ; Holst CL; Martin GS; Naicker KP; Vellekoop S; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Kozlowski JA
Bioorg Med Chem Lett; 2016 Mar; 26(5):1475-9. PubMed ID: 26850003
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent macrocyclic HCV NS5A inhibitors.
Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA
Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743
[TBL] [Abstract][Full Text] [Related]
4. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA
Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742
[TBL] [Abstract][Full Text] [Related]
5. MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.
Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer M; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Asante-Appiah E; Kozlowski JA
Bioorg Med Chem Lett; 2018 Jun; 28(10):1954-1957. PubMed ID: 29653894
[TBL] [Abstract][Full Text] [Related]
6. Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi
Link JO; Taylor JG; Trejo-Martin A; Kato D; Katana AA; Krygowski ES; Yang ZY; Zipfel S; Cottell JJ; Bacon EM; Tran CV; Yang CY; Wang Y; Wang KW; Zhao G; Cheng G; Tian Y; Gong R; Lee YJ; Yu M; Gorman E; Mogalian E; Perry JK
Bioorg Med Chem Lett; 2019 Aug; 29(16):2415-2427. PubMed ID: 31230974
[TBL] [Abstract][Full Text] [Related]
7. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
Yu W; Coburn CA; Nair AG; Wong M; Rosenblum SB; Zhou G; Dwyer MP; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Kim SH; Zeng Q; Selyutin O; Chen L; Masse F; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Lin M; Kozlowski JA
Bioorg Med Chem Lett; 2016 Aug; 26(15):3414-20. PubMed ID: 27394665
[TBL] [Abstract][Full Text] [Related]
8. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
Gao M
Curr Opin Virol; 2013 Oct; 3(5):514-20. PubMed ID: 23896281
[TBL] [Abstract][Full Text] [Related]
9. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.
Coburn CA; Meinke PT; Chang W; Fandozzi CM; Graham DJ; Hu B; Huang Q; Kargman S; Kozlowski J; Liu R; McCauley JA; Nomeir AA; Soll RM; Vacca JP; Wang D; Wu H; Zhong B; Olsen DB; Ludmerer SW
ChemMedChem; 2013 Dec; 8(12):1930-40. PubMed ID: 24127258
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants.
Yu W; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Coburn CA; Selyutin O; Chen L; Rokosz L; Agrawal S; Liu R; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
J Med Chem; 2016 Nov; 59(22):10228-10243. PubMed ID: 27792320
[TBL] [Abstract][Full Text] [Related]
11. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
Lee C
Arch Pharm Res; 2011 Sep; 34(9):1403-7. PubMed ID: 21975800
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
Gottwein JM; Pham LV; Mikkelsen LS; Ghanem L; Ramirez S; Scheel TKH; Carlsen THR; Bukh J
Gastroenterology; 2018 Apr; 154(5):1435-1448. PubMed ID: 29274866
[TBL] [Abstract][Full Text] [Related]
13. Discovery of fluorobenzimidazole HCV NS5A inhibitors.
Randolph JT; Flentge CA; Donner P; Rockway TW; Patel SV; Nelson L; Hutchinson DK; Mondal R; Mistry N; Reisch T; Dekhtyar T; Krishnan P; Pilot-Matias T; Stolarik DF; Beno DWA; Wagner R; Maring C; Kati WM
Bioorg Med Chem Lett; 2016 Nov; 26(22):5462-5467. PubMed ID: 27780635
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.
Court JJ; Poisson C; Ardzinski A; Bilimoria D; Chan L; Chandupatla K; Chauret N; Collier PN; Das SK; Denis F; Dorsch W; Iyer G; Lauffer D; L'Heureux L; Li P; Luisi BS; Mani N; Nanthakumar S; Nicolas O; Rao BG; Ronkin S; Selliah S; Shawgo RS; Tang Q; Waal ND; Yannopoulos CG; Green J
J Med Chem; 2016 Jul; 59(13):6293-302. PubMed ID: 27366941
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
Yu W; Hu B; Zhong B; Hao J; Lei Z; Agrawal S; Rokosz L; Liu R; Chen S; Asante-Appiah E; Kozlowski JA
Bioorg Med Chem Lett; 2019 Mar; 29(5):700-706. PubMed ID: 30711390
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors.
Ivashchenko AA; Ivanenkov YA; Aladinskiy VA; Karapetian RN; Koryakova AG; Ryakhovskiy AA; Mitkin OD; Kravchenko DV; Savchuk NP; Zagribelnyy BA; Ivashchenko AV
Bioorg Med Chem; 2020 Oct; 28(20):115716. PubMed ID: 33069072
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.
Ramdas V; Talwar R; Banerjee M; Joshi AA; Das AK; Walke DS; Borhade P; Dhayagude U; Loriya R; Gote G; Bommakanti A; Sivaram A; Agarwal G; Goswami A; Nigade P; Mehta M; Patil V; Modi D; Kumar H; Mallurwar S; Dash A; Modi F; Kuldharan S; Srivastava P; Singh M; Narasimham L; Gundu J; Sharma S; Kamboj RK; Palle VP
J Med Chem; 2019 Dec; 62(23):10563-10582. PubMed ID: 31710479
[TBL] [Abstract][Full Text] [Related]
18. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
[TBL] [Abstract][Full Text] [Related]
19.
Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
[TBL] [Abstract][Full Text] [Related]
20. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
